Article

Hyperinflammation in airways of cystic fibrosis patients: what's new?

UMR-S U893, UPMC, Paris 6, 184, Rue du Fg Saint-Antoine, 75571 Paris cedex 12, France.
Expert Review of Molecular Diagnostics (impact factor: 4.86). 08/2008; 8(4):359-63. DOI:10.1586/14737159.8.4.359 pp.359-63
Source: PubMed
0 0
 · 
0 Bookmarks
 · 
33 Views
  • Source
    Article: Infection, inflammation, and the downward spiral of cystic fibrosis lung disease.
    Richard B Moss
    The Journal of pediatrics 03/2009; 154(2):162-3. · 4.02 Impact Factor
  • Source
    Article: High-Dose Ibuprofen in Cystic Fibrosis
    Larry C. Lands, Dauletbaev Nurlan
    [show abstract] [hide abstract]
    ABSTRACT: Cystic Fibrosis (CF) is the most common lethal genetic disorder in North America and Europe. Most patients succumb to progressive lung disease characterized by an exaggerated neutrophilic inflammation. In animal models of chronic infection, high-dose ibuprofen was demonstrated to reduce inflammation without hindering bacterial clearance. This led to two clinical trials, which demonstrated a benefit in slowing the progression of lung disease in CF. However, concerns about potential adverse effects have limited the use of high-dose ibuprofen in CF patients. There are a variety of potential mechanisms to account for the observed clinical benefit. A better understanding of these mechanisms could potentially lead to more targeted and better-tolerated anti-inflammatory therapies.
    Pharmaceuticals. 01/2010;
  • Source
    Article: A roadmap to the brittle bones of cystic fibrosis.
    Ashwini P Gore, Soon Ho Kwon, Antine E Stenbit
    [show abstract] [hide abstract]
    ABSTRACT: Cystic fibrosis (CF) is an autosomal recessive disorder which despite advances in medical care continues to be a life-limiting and often fatal disease. With increase in life expectancy of the CF population, bone disease has emerged as a common complication. Unlike the osteoporosis seen in postmenopausal population, bone disease in CF begins at a young age and is associated with significant morbidity due to fractures, kyphosis, increased pain, and decreased lung function. The maintenance of bone health is essential for the CF population during their lives to prevent pain and fractures but also as they approach lung transplantation since severe bone disease can lead to exclusion from lung transplantation. Early recognition, prevention, and treatment are key to maintaining optimal bone health in CF patients and often require a multidisciplinary approach. This article will review the pathophysiology, current clinical practice guidelines, and potential future therapies for treating CF-related bone disease.
    Journal of osteoporosis. 01/2010; 2011:926045.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.